Linawati Hananta, Linawati
Department Of Pharmacology, School Of Medicine And Health Sciences, Universitas Katolik Indonesia Atma Jaya, Jl. Pluit Raya No 2, Jakarta 14440

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 23 Documents
Search

Transcriptional Regulation of CYP2D6 by Nrf2 and Its Implications in Breast Cancer Therapy: Bioinformatics and Experimental Evidence Ferbian Milas Siswanto; Maria Dara Novi Handayani; Lonah Lonah; Rita Dewi; Zita Arieselia; Linawati Hananta; Putu Suwarastra Andarisuta
The Indonesian Biomedical Journal Vol 17, No 1 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i1.3194

Abstract

BACKGROUND: Tamoxifen (TAM) resistance in patient with breast cancer is the leading cause of mortality among women globally. Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of TAM, and recently NF-E2-related factor 2 (Nrf2) has recently been found as its regulator. However, the impact of Nrf2-mediated CYP2D6 regulation in the context of breast cancer and TAM resistance are currently unknown. Therefore, this study was conducted to examine the role of CYP2D6 and Nrf2 in breast cancer prognosis. MEDTHODS: The roles of CYP2D6 and Nrf2 were investigated in the T47D breast cancer cell line and T47D-derived TAM-resistant cells by examining the gene expression, cell viability, and transcriptional regulation by quantitative reverse transcription polymerase chain reaction (qRT-PCR), MTT, and reporter gene assay, respectively. Additionally, comprehensive in silico analysis of the transcriptomic and clinical data from The Cancer Genome Atlas database were performed to uncover the prognostic role of CYP2D6 and its regulator in breast cancer patients. RESULTS: CYP2D6 mRNA was low and Nrf2 protein was high in TAM-resistant T47D cells compared to parental cells. Nrf2 knockdown upregulated CYP2D6 mRNA levels and enhanced the cytotoxicity of TAM. Similarly, in silico analysis revealed that low CYP2D6 mRNA and high Nrf2 protein were related to a lower probability of survival. The rs1238662089 within the identified Nrf2-binding site was found to greatly affect CYP2D6 expression levels, indicating its role as predictor for better prognosis. CONCLUSION: This study revealed for the first time that Nrf2 regulates CYP2D6expression in breast cancer and is involved in TAM sensitivity; thus, plays a role in breast cancer patient prognosis.KEYWORDS: breast cancer, CYP2D6, Nrf2, pharmacoepigenetics, SNPs
THE RELATIONSHIP BETWEEN VITAMIN D LEVELS AND URIC ACID LEVELS IN THE ELDERLY AT SANTA ANNA NURSING HOME Ester Elida O Harita; Felicia Kurniawan; Linawati Hananta; Isadora Gracia Sahusilawane
Journal of Social Research Vol. 3 No. 2 (2024): Journal of Social Research
Publisher : International Journal Labs

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55324/josr.v3i2.1929

Abstract

As a person ages, the physiological function of the body decreases so that the risk of vitamin D deficiency and gout. The increasing elderly population can create a new era, namely the aging population. This study aims to see the relationship between vitamin D levels and uric acid levels in the elderly at Santa Anna Nursing Home. This study is an analytical observational study with a cross-sectional design with 70 elderly respondents living in Santa Anna Nursing Home, Jakarta. The correlation test is performed using the Pearson Correlation Test. There is a significant negative relationship between vitamin D levels and uric acid levels. In 23 elderly obtained average vitamin D levels of 36.9 + 8.4 ng / mL while high uric acid as many as 23 elderly (46%) with an average of 6.24 ± 1.9 mg / mL. From bivariate analysis, vitamin D levels were significantly associated with uric acid levels (r: -0.295, p: 0.037). There was a significant relationship between vitamin D levels and uric acid levels in the elderly at Santa Anna Nursing Home with a value of p = 0.041 (p < 0.05)
Therapeutic Potential of Bovine Lactoferrin to Reduce Brain Malondialdehyde Levels in Hyperlipidemia-Induced Sprague-Dawley Rats Havian Daulung Telium; Tena Djuartina; Dion Notario; Linawati Hananta
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 9, No 2 (2024)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v9i2.72048

Abstract

Hyperlipidemia is a medical condition that can trigger various diseases, one of which is a neurodegenerative or neurological disease. Lactoferrin is known to have multiple protective activities, one of which is antioxidant. This study aimed to determine the potential of lactoferrin bovine to decrease brain MDA levels in Sprague-Dawley (SD) rats induced by hyperlipidemia. This study was an in vivo experimental study using 24 male SD rats divided into six groups: normal, negative control, positive control, low-dose bovine lactoferrin (LLF), intermediate-dose bovine lactoferrin (ILF), and high-dose bovine lactoferrin (HLF). The diet in the normal group was the standard diet, and the other groups were induced by a high-fat diet (HFD). The intervention for the positive control group was simvastatin. In contrast, LLF, ILF, and HLF groups were given bovine lactoferrin doses of 100, 200, and 400 mg/kgBW, respectively. After seven weeks, all rats were necropsied, and their brains were taken to be tested for malondialdehyde (MDA) levels with an MDA assay kit using a spectrophotometer. Data was then analyzed using Shapiro-Wilk and Levene test and continued with one-way ANOVA and post-hoc Tukey test. There were significant differences (p&lt;0.05) between the negative control group (269.99±13.50 nmol/g weight) and every bovine lactoferrin groups (219.92±22.99 nmol/g weight, 151.60±23.43 nmol/g weight, 158.16±12.33 nmol/g weight, respectively) in reducing brain MDA levels. In summary, all bovine lactoferrin groups (100, 200, and 400 mg/kgBW) significantly reduced brain MDA levels of SD rats in hyperlipidemia condition.
Co-Authors Ageng, Leonardo Ahmad Hamim Sadewa Amelia, Margareta Arrang, Sherly Tandi Bai Apris Bansai Immanuel Bertha Soegiarto, Bertha Bryan Junius Winata Budiyanti, Ecie Chandra, Gerard Justin Chandra, Valencia Darojatun Ida Dharmalau, Richanda Surya Dion Notario Dion Notario Divara Ariesta Sekar Suryadi, Made Edward Surjono, Edward Endrardewi, Naomi Arumratri Erfen Gustiawan Suwangto, Erfen Gustiawan Eriady, Angely Margaretha Ester Elida O Harita Evi Ulina Margaretha Situmorang Fan, Tan Fei Felicia Kurniawan Felicia Kurniawan, Felicia Fenny Mariska Ferbian Milas Siswanto Gaverio, Nicholas Francisco Ghea Mangkuliguna Gonga, Audrey Aprilia Hardi, Nicholas Hari Kusnanto Havian Daulung Telium Isadora Gracia Sahusilawane Isadora Gracia, Isadora Jonny Setiawan Jonny Setiawan Jonny Setiawan Jontari Hutagalung Joprang, Freggy Spicano Jusni, Louis Fabio Jonathan Kesuma , Deony Maria Kik Hao Samuel Kurniawan, Sandy Vitria Labaran, Victor Carolus Christiputra Larasati, Victoria Lee, Jocelyn Viony Lieputra, Andrew Adhytia Lonah, Lonah Mahaputra Mahaputra Marcella, Laurie Margareta Amelia Maria Dara Novi Handayani, Maria Dara Novi Mariani Santosa, Mariani Mega Tyas Prihatin Meiliyana Wijaya Monalisa Heryani Mora Octavia Nathalie, Evadia Nawanto Agung Prastowo Novijanti Rintis Oenang, Nydia Olivia, Vera P. Purwono Prayoga Tjendratama, Jason Puspa Bunardi, Dewi Putri, Indira Ayu Putu Suwarastra Andarisuta Rita Dewi Rita Dewi Rita Dewi Rita Dewi Dewi S. Supargiyono Sahusilawane, Isadora Gracia Satyagraha Ari Winasti Sri Hapsari Wijayanti Sulisthio , Manuel Omar Weki Surilena Hasan Tandi, Sherly Tena Djuartina Tena Djuartina, Tena Theja , Berliana Elyza Suryadi Triwibowo A. Garjito Vallerie Satyadi, Richelle Veronika Maria Sidharta Vetinly Vetinly Via Dolorosa Halilintar Wea, Brigitta Yuliana Widodo, Jerico Tristan Wijaya, Jullyany Waty Wijaya, Meiliyana Yolanda, Ellysa Yudy Yuliana Yuliana Yulius Evan Christian Yunisa Astiarani Zita Arieselia